PSTI Financial Facts
Research and development expenses: -6.03MBasic and diluted net loss per share: -0.08
See Full Income Statement
Total long-term liabilities: 1.93M
Total current assets: 30.31M
See Full Balance Sheet
Pluristem Therapeutics Inc. (PSTI) Earnings
|
Expand Research on PSTI
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | N/A | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | N/A | Normal Earnings Time | N/A |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9/12/22 | Q222 | N/A | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A |
